Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Joins Russia Land Rush, But Chooses To Partner Rather Than Build

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer Inc. has signed a memorandum of understanding with ChemRar High Tech Center, a Moscow incubator, to explore a collaboration focused on research, development and commercialization of innovative drugs in Russia and other countries.

You may also be interested in...



Russia's First BioPharma Public-Private Partnership Eyes Bio-Betters, Attracts $110 million

Russia's bid to catch up in the global race to establish a recognized biopharma sector picked up speed with the Aug. 4 announcement of SynBio, a $110 million joint venture to develop bio-betters and innovative medicines for the Russian and international markets.

Russia's First BioPharma Public-Private Partnership Eyes Bio-Betters, Attracts $110 million

Russia's bid to catch up in the global race to establish a recognized biopharma sector picked up speed with the Aug. 4 announcement of SynBio, a $110 million joint venture to develop bio-betters and innovative medicines for the Russian and international markets.

Novartis, AstraZeneca Pledge Support For Russia At St. Petersburg Economic Forum In Latest Big Pharma Move To Go Local

Russia Premier Vladimir Putin has said he wants multinational pharmaceutical companies to manufacture drugs in Russia and support development of the local industry as part of a $4 billion government initiative to reform the Russia healthcare market by 2020. So perhaps it is not too surprising that both Novartis AG and AstraZeneca PLC chose to re-emphasize their commitments to Russia by each issuing press releases June 16 to coincide with the kickoff of the St. Petersburg International Economic Forum

Related Content

Topics

UsernamePublicRestriction

Register

LL1135972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel